301126 达嘉维康
已收盘 10-27 15:00:00
资讯
新帖
简况
达嘉维康（301126）2026年三季报简析：净利润同比增长91.98%，商誉占比较高
证券之星 · 10-24
达嘉维康（301126）2026年三季报简析：净利润同比增长91.98%，商誉占比较高
股市必读：达嘉维康新发布《关于对外担保的进展公告》
证券之星 · 10-23
股市必读：达嘉维康新发布《关于对外担保的进展公告》
图解达嘉维康三季报：第三季度单季净利润同比下降39.83%
证券之星 · 10-23
图解达嘉维康三季报：第三季度单季净利润同比下降39.83%
达嘉维康：公司相关产品主要用于说明书载明的适应症
证券之星 · 10-19
达嘉维康：公司相关产品主要用于说明书载明的适应症
股市必读：达嘉维康(301126)股东户数1.33万户，较上期减少2.9%
证券之星 · 10-19
股市必读：达嘉维康(301126)股东户数1.33万户，较上期减少2.9%
达嘉维康(301126)10月9日股东户数1.33万户，较上期减少2.9%
证券之星 · 10-16
达嘉维康(301126)10月9日股东户数1.33万户，较上期减少2.9%
达嘉维康：截止2026年10月9日，公司股东人数为13,288人
证券之星 · 10-16
达嘉维康：截止2026年10月9日，公司股东人数为13,288人
股市必读：达嘉维康（301126）9月28日董秘有最新回复
证券之星 · 09-29
股市必读：达嘉维康（301126）9月28日董秘有最新回复
股市必读：达嘉维康（301126）9月17日董秘有最新回复
证券之星 · 09-18
股市必读：达嘉维康（301126）9月17日董秘有最新回复
股市必读：达嘉维康(301126)股东户数1.37万户，较上期减少4.83%
证券之星 · 09-07
股市必读：达嘉维康(301126)股东户数1.37万户，较上期减少4.83%
达嘉维康(301126)8月31日股东户数1.37万户，较上期减少4.83%
证券之星 · 09-04
达嘉维康(301126)8月31日股东户数1.37万户，较上期减少4.83%
达嘉维康：截止2026年8月31日，公司股东人数为13,685人
证券之星 · 09-04
达嘉维康：截止2026年8月31日，公司股东人数为13,685人
达嘉维康（301126）披露2026年半年度报告，8月31日股价上涨0.77%
证券之星 · 08-31
达嘉维康（301126）披露2026年半年度报告，8月31日股价上涨0.77%
达嘉维康(301126)8月10日股东户数1.44万户，较上期增加5.75%
证券之星 · 08-29
达嘉维康(301126)8月10日股东户数1.44万户，较上期增加5.75%
图解达嘉维康中报：第二季度单季净利润同比增长157.38%
证券之星 · 08-29
图解达嘉维康中报：第二季度单季净利润同比增长157.38%
公司问答丨达嘉维康：已与湖南省医疗保障局电子处方流转平台完成了系统对接
格隆汇 · 08-17
公司问答丨达嘉维康：已与湖南省医疗保障局电子处方流转平台完成了系统对接
达嘉维康：公司从单纯“卖药品”向“药学服务、慢病管理、互联网医药”等综合健康服务转型
证券之星 · 08-05
达嘉维康：公司从单纯“卖药品”向“药学服务、慢病管理、互联网医药”等综合健康服务转型
达嘉维康：聚焦再生医学在疾病诊断、精准治疗及健康管理等关键领域的前沿产品与突破性技术的开发
证券之星 · 08-05
达嘉维康：聚焦再生医学在疾病诊断、精准治疗及健康管理等关键领域的前沿产品与突破性技术的开发
股市必读：达嘉维康新发布《关于对外担保的进展公告》
证券之星 · 08-03
股市必读：达嘉维康新发布《关于对外担保的进展公告》
达嘉维康（301126）披露完成工商变更登记并换发营业执照公告，7月28日股价上涨0.82%
证券之星 · 07-28
达嘉维康（301126）披露完成工商变更登记并换发营业执照公告，7月28日股价上涨0.82%
加载更多
公司概况
公司名称：
达嘉维康生物医药产业集团股份有限公司
所属行业：
批发业
上市日期：
2021-12-07
主营业务：
达嘉维康生物医药产业集团股份有限公司的主营业务是药品、生物制品、医疗器械等产品的分销及零售业务。公司的主要产品是小建中颗粒、五味安神颗粒、九味肝泰胶囊、小儿咽扁颗粒、新生化颗粒、阿奇霉素颗粒。
发行价格：
12.37
{"stockData":{"symbol":"301126","market":"SZ","secType":"STK","nameCN":"达嘉维康","latestPrice":8.89,"timestamp":1793084595000,"preClose":9.4,"halted":0,"volume":3610066,"delay":0,"changeRate":-0.0543,"floatShares":140000000,"shares":204999999,"eps":-1.1576,"marketStatus":"已收盘","change":-0.51,"latestTime":"10-27 15:00:00","open":9.38,"high":9.54,"low":8.89,"amount":33053600,"amplitude":0.0691,"askPrice":8.89,"askSize":70,"bidPrice":8.88,"bidSize":39,"shortable":0,"etf":0,"ttmEps":-1.1576,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793151000000},"marketStatusCode":5,"adr":0,"adjPreClose":9.4,"symbolType":"stock","openAndCloseTimeList":[[1793064600000,1793071800000],[1793077200000,1793084400000]],"highLimit":10.34,"lowLimit":8.46,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":205403200,"isCdr":false,"pbRate":1.28,"roa":"--","roe":"0.62%","epsLYR":-1.18,"committee":-0.385475,"marketValue":1826000000,"turnoverRate":0.0259,"status":1,"floatMarketCap":1240000000},"requestUrl":"/m/hq/s/301126","defaultTab":"news","newsList":[{"id":"2677707799","title":"达嘉维康（301126）2026年三季报简析：净利润同比增长91.98%，商誉占比较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2677707799","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677707799?lang=zh_cn&edition=full","pubTime":"2026-10-24 06:12","pubTimestamp":1792793526,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期达嘉维康发布2026年三季报。根据财报显示，达嘉维康净利润同比增长91.98%，商誉占比较高。截至本报告期末，公司营业总收入40.37亿元，同比下降2.24%，归母净利润978.6万元，同比上升91.98%。按单季度数据看，第三季度营业总收入13.36亿元，同比下降6.05%，第三季度归母净利润252.95万元，同比下降39.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400005480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677899239","title":"股市必读：达嘉维康新发布《关于对外担保的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677899239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677899239?lang=zh_cn&edition=full","pubTime":"2026-10-23 05:27","pubTimestamp":1792704432,"startTime":"0","endTime":"0","summary":"公司公告汇总关于对外担保的进展公告达嘉维康为控股子公司安徽达嘉维康提供1,500万元连带责任保证担保，为全资子公司湖南达嘉维康医药有限公司提供24,000万元连带责任保证担保。截至公告日，公司及控股子公司累计担保余额为143,319.72万元，占最近一期经审计净资产的96.33%。本次计提减少公司2026年第三季度利润总额17,683,856.68元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300004717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677996012","title":"图解达嘉维康三季报：第三季度单季净利润同比下降39.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677996012","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677996012?lang=zh_cn&edition=full","pubTime":"2026-10-23 01:03","pubTimestamp":1792688601,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康2026年三季报显示，前三季度公司主营收入40.37亿元，同比下降2.24%；归母净利润978.6万元，同比上升91.98%；扣非净利润1050.7万元，同比上升170.68%；其中2026年第三季度，公司单季度主营收入13.36亿元，同比下降6.05%；单季度归母净利润252.95万元，同比下降39.83%；单季度扣非净利润203.79万元，同比下降55.76%；负债率73.64%，投资收益20.07万元，财务费用8153.9万元，毛利率18.39%。财报数据概要请见下图:本文数据来源于达嘉维康2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300001303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676505930","title":"达嘉维康：公司相关产品主要用于说明书载明的适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2676505930","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676505930?lang=zh_cn&edition=full","pubTime":"2026-10-19 15:27","pubTimestamp":1792394832,"startTime":"0","endTime":"0","summary":"公司旗下天济草堂、达嘉维康生物制药等子公司的产品管线包括磷酸奥司他韦颗粒、盐酸莫西沙星片、清热散结胶囊、小儿氨酚黄那敏颗粒、板蓝根颗粒、阿奇霉素颗粒、玉叶清火胶囊及小儿咽扁颗粒等产品，主要用于相关产品说明书载明的适应症，包括流感防治、感冒发热、咽喉肿痛、呼吸道感染及其他相应症状的对症治疗。其中，抗感染药物主要针对相应的细菌感染，并不用于治疗病毒本身，患者不应自行使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900013235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676557371","title":"股市必读：达嘉维康(301126)股东户数1.33万户，较上期减少2.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676557371","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676557371?lang=zh_cn&edition=full","pubTime":"2026-10-19 04:09","pubTimestamp":1792354151,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘，达嘉维康报收于9.95元，上涨0.61%，换手率2.68%，成交量3.74万手，成交额3781.92万元。股本股东变化：截至2026年10月9日，达嘉维康股东户数为1.33万户，较8月31日减少2.9%。股本股东变化股东户数变动截至2026年10月9日公司股东户数为1.33万户，较8月31日减少397.0户，减幅为2.9%；户均持股数量由上期的1.5万股增至1.55万股，户均持股市值为16.34万元。谢谢董秘： 您好，截止2026年10月9日，公司股东人数为13,288人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900001296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675598542","title":"达嘉维康(301126)10月9日股东户数1.33万户，较上期减少2.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675598542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675598542?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:26","pubTimestamp":1792142764,"startTime":"0","endTime":"0","summary":"证券之星消息，近日达嘉维康披露，截至2026年10月9日公司股东户数为1.33万户，较8月31日减少397.0户，减幅为2.9%。在医药商业行业个股中，达嘉维康股东户数低于行业平均水平，截至10月9日，医药商业行业平均股东户数为4.3万户。从股价来看，2026年8月31日至2026年10月9日，达嘉维康区间涨幅为1.34%，在此期间股东户数减少397.0户，减幅为2.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600029510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675456453","title":"达嘉维康：截止2026年10月9日，公司股东人数为13,288人","url":"https://stock-news.laohu8.com/highlight/detail?id=2675456453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675456453?lang=zh_cn&edition=full","pubTime":"2026-10-16 15:45","pubTimestamp":1792136718,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康(301126)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司最新一期的股东人数是多少？谢谢达嘉维康回复：您好，截止2026年10月9日，公司股东人数为13,288人。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600022860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671523002","title":"股市必读：达嘉维康（301126）9月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2671523002","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671523002?lang=zh_cn&edition=full","pubTime":"2026-09-29 02:21","pubTimestamp":1790619668,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，达嘉维康报收于10.31元，下跌0.48%，换手率2.37%，成交量3.31万手，成交额3411.33万元。董秘最新回复投资者： 您好！请问截至9月20日公司股东人数是多少，谢谢董秘： 您好，为保证所有投资者平等地获取公司信息，关于股东人数等具体信息，请您查阅公司披露的定期报告。当日关注点交易信息汇总：9月28日主力资金净流出84.76万元，占总成交额2.48%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900002150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668499978","title":"股市必读：达嘉维康（301126）9月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2668499978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668499978?lang=zh_cn&edition=full","pubTime":"2026-09-18 00:47","pubTimestamp":1789663633,"startTime":"0","endTime":"0","summary":"截至2026年9月17日收盘，达嘉维康报收于10.1元，上涨1.3%，换手率1.57%，成交量2.19万手，成交额2193.04万元。董秘最新回复投资者： 请问截止2026年9月10日，公司股东人数多少？当日关注点交易信息汇总：9月17日达嘉维康主力资金净流出113.2万元，占总成交额5.16%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800000409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665359367","title":"股市必读：达嘉维康(301126)股东户数1.37万户，较上期减少4.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665359367","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665359367?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:41","pubTimestamp":1788716468,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，达嘉维康报收于10.33元，下跌0.58%，换手率1.72%，成交量2.4万手，成交额2500.55万元。股本股东变化：截至2026年8月31日，达嘉维康股东户数为1.37万户，较8月10日减少694户，减幅4.83%。交易信息汇总资金流向9月4日主力资金净流出25.12万元，占总成交额1.0%；游资资金净流出52.76万元，占总成交额2.11%；散户资金净流入77.88万元，占总成交额3.11%。户均持股数量由上期的1.43万股增加至1.5万股，户均持股市值为15.65万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733364","title":"达嘉维康(301126)8月31日股东户数1.37万户，较上期减少4.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733364","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664733364?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:37","pubTimestamp":1788514665,"startTime":"0","endTime":"0","summary":"证券之星消息，近日达嘉维康披露，截至2026年8月31日公司股东户数为1.37万户，较8月10日减少694.0户，减幅为4.83%。在医药商业行业个股中，达嘉维康股东户数低于行业平均水平，截至8月31日，医药商业行业平均股东户数为4.28万户。从股价来看，2026年8月10日至2026年8月31日，达嘉维康区间涨幅为5.67%，在此期间股东户数减少694.0户，减幅为4.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400031102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386897","title":"达嘉维康：截止2026年8月31日，公司股东人数为13,685人","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664386897?lang=zh_cn&edition=full","pubTime":"2026-09-04 11:38","pubTimestamp":1788493097,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康(301126)09月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司截止8月31日最新股东数？达嘉维康回复：您好，截止2026年8月31日，公司股东人数为13,685人。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400016829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663773400","title":"达嘉维康（301126）披露2026年半年度报告，8月31日股价上涨0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663773400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663773400?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:03","pubTimestamp":1788174185,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，达嘉维康报收于10.43元，较前一交易日上涨0.77%，最新总市值为21.42亿元。该股当日开盘10.26元，最高10.47元，最低10.11元，成交额达4092.87万元，换手率为2.83%。公司于近日披露《2026年半年度报告》。报告显示，本报告期营业收入为2,701,647,581.95元，较上年同期的2,708,337,434.78元下降0.25%。归属于上市公司股东的净利润为7,256,514.92元，同比增长712.11%；扣除非经常性损益后的净利润为8,469,084.58元，同比增长1,269.15%。经营活动产生的现金流量净额为11,472,736.91元，同比上升107.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100030005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663901217","title":"达嘉维康(301126)8月10日股东户数1.44万户，较上期增加5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663901217","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663901217?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:20","pubTimestamp":1787995208,"startTime":"0","endTime":"0","summary":"证券之星消息，近日达嘉维康披露，截至2026年8月10日公司股东户数为1.44万户，较6月30日增加782.0户，增幅为5.75%。在医药商业行业个股中，达嘉维康股东户数低于行业平均水平，截至8月10日，医药商业行业平均股东户数为4.34万户。从股价来看，2026年6月30日至2026年8月10日，达嘉维康区间涨幅为15.44%，在此期间股东户数增加782.0户，增幅为5.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013562","title":"图解达嘉维康中报：第二季度单季净利润同比增长157.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013562","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663013562?lang=zh_cn&edition=full","pubTime":"2026-08-29 03:43","pubTimestamp":1787946198,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康2026年中报显示，上半年度公司主营收入27.02亿元，同比下降0.25%；归母净利润725.65万元，同比上升712.11%；扣非净利润846.91万元，同比上升1269.15%；其中2026年第二季度，公司单季度主营收入13.17亿元，同比下降6.47%；单季度归母净利润129.16万元，同比上升157.38%；单季度扣非净利润281.01万元，同比上升263.01%；负债率74.42%，投资收益17.73万元，财务费用5435.44万元，毛利率18.3%。财报数据概要请见下图:本文数据来源于达嘉维康2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900007601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660488314","title":"公司问答丨达嘉维康：已与湖南省医疗保障局电子处方流转平台完成了系统对接","url":"https://stock-news.laohu8.com/highlight/detail?id=2660488314","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660488314?lang=zh_cn&edition=full","pubTime":"2026-08-17 15:43","pubTimestamp":1786952600,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0250","159891","301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657596837","title":"达嘉维康：公司从单纯“卖药品”向“药学服务、慢病管理、互联网医药”等综合健康服务转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2657596837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657596837?lang=zh_cn&edition=full","pubTime":"2026-08-05 08:57","pubTimestamp":1785891427,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康08月04日在投资者关系平台上答复投资者关心的问题。公司从单纯 “卖药品” 向 “药学服务、慢病管理、互联网医药” 等综合健康服务转型，是顺应行业发展趋势、提升客户黏性和经营质量的重要方向，也是公司未来持续推进的重要战略之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500009689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657595428","title":"达嘉维康：聚焦再生医学在疾病诊断、精准治疗及健康管理等关键领域的前沿产品与突破性技术的开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2657595428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657595428?lang=zh_cn&edition=full","pubTime":"2026-08-05 08:39","pubTimestamp":1785890345,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康08月04日在投资者关系平台上答复投资者关心的问题。公司聚焦再生医学在疾病诊断、精准治疗及健康管理等关键领域的前沿产品与突破性技术的开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500009499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656343995","title":"股市必读：达嘉维康新发布《关于对外担保的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656343995?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:59","pubTimestamp":1785697148,"startTime":"0","endTime":"0","summary":"公司公告汇总：达嘉维康为子公司及合作门店提供合计2.084亿元连带责任保证，累计担保余额160,195.98万元，占最近一期经审计净资产的107.67%。公司公告汇总关于对外担保的进展公告湖南达嘉维康医药产业股份有限公司为全资子公司湖南达嘉维康医药有限公司提供16,000万元最高额连带责任保证，为控股子公司宁夏德立信医药有限责任公司提供2,000万元连带责任保证，为山西思迈乐药业连锁有限公司旗下10家门店合计提供2,840万元连带责任保证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654883572","title":"达嘉维康（301126）披露完成工商变更登记并换发营业执照公告，7月28日股价上涨0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654883572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654883572?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:36","pubTimestamp":1785249376,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，达嘉维康报收于8.63元，较前一交易日上涨0.82%，最新总市值为17.73亿元。近日，达嘉维康发布《关于完成工商变更登记并换发营业执照的公告》。公司已近日完成工商变更登记及《公司章程》备案手续，并取得长沙市市场监督管理局换发的营业执照。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800040080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793118994510,"stockEarnings":[{"period":"1week","weight":-0.0844},{"period":"1month","weight":-0.1419},{"period":"3month","weight":0.0207},{"period":"6month","weight":-0.2523},{"period":"1year","weight":-0.2651},{"period":"ytd","weight":-0.2766}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.0471},{"period":"6month","weight":-0.1128},{"period":"1year","weight":-0.0872},{"period":"ytd","weight":-0.0808}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"达嘉维康生物医药产业集团股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"13288人(较上一季度减少0.29%)","perCapita":"10499股","listingDate":"2021-12-07","address":"湖南省长沙市岳麓区茯苓路30号","registeredCapital":"20540万元","survey":" 达嘉维康生物医药产业集团股份有限公司的主营业务是药品、生物制品、医疗器械等产品的分销及零售业务。公司的主要产品是小建中颗粒、五味安神颗粒、九味肝泰胶囊、小儿咽扁颗粒、新生化颗粒、阿奇霉素颗粒。","listedPrice":12.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"达嘉维康(301126)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供达嘉维康(301126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"达嘉维康,301126,达嘉维康股票,达嘉维康股票老虎,达嘉维康股票老虎国际,达嘉维康行情,达嘉维康股票行情,达嘉维康股价,达嘉维康股市,达嘉维康股票价格,达嘉维康股票交易,达嘉维康股票购买,达嘉维康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"达嘉维康(301126)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供达嘉维康(301126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}